D Huglo
Overview
Explore the profile of D Huglo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
867
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Morschhauser F, Dekyndt B, Baillet C, Barthelemy C, Malek E, Fulcrand J, et al.
Sci Rep
. 2018 Oct;
8(1):14860.
PMID: 30291297
Monoclonal antibodies (mAbs) are key components in several therapies for cancer and inflammatory diseases but current knowledge of their clinical pharmacokinetics and distribution in human tissues remains incomplete. Consequently, optimal...
2.
Adens A, Landy P, Terriou L, Baillet C, Beron A, Lambert M, et al.
Rev Med Interne
. 2017 Mar;
38(4):235-242.
PMID: 28268124
Introduction: Erdheim-Chester disease is a rare form of non-langerhans histiocytosis and its etiology is still not well established. The aims of the study were to assess the value of the...
3.
Soudet S, Lambert M, Lefevre G, Maillard H, Huglo D, Hatron P
Pharmacol Res
. 2017 Feb;
119:237-239.
PMID: 28212888
Introduction: Idiopathic cyclic edema (ICE) is a rare cause of edema. To date, there is no standard of care. The physiopathology of ICE could be explained by an impairment of...
4.
Rossignol J, Terriou L, Robu D, Willekens C, Hivert B, Pascal L, et al.
Am J Transplant
. 2015 Apr;
15(7):1976-81.
PMID: 25868706
Posttransplantation lymphoproliferative disorders (PTLDs) are life-threatening complications after solid organ and hematopoietic stem cell transplantation. Only half of CD20-positive PTLDs respond to rituximab monotherapy, and outcomes remain poor for patients...
5.
Ferrer L, Malek E, Bodet-Milin C, Legouill S, Prangere T, Robu D, et al.
Q J Nucl Med Mol Imaging
. 2013 Jan;
56(6):529-37.
PMID: 23358406
Aim: The aim of this study was to compare different dosimetric approaches on therapy naïve patients enrolled in a multicentre fractionated radioimmunotherapy trial, to determine which methodological approach correlates with...
6.
Stavris C, Lambert M, Lefevre G, Mirault T, Pape E, Buchdahl-Duchange A, et al.
Rev Med Interne
. 2011 May;
32(7):447-50.
PMID: 21601965
No abstract available.
7.
Lopci E, Santi I, Derenzini E, Fonti C, Savelli G, Bertagna F, et al.
Ann Oncol
. 2010 Feb;
21(9):1877-1883.
PMID: 20147744
Background: The aim of this study is the 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG)-positron emission tomography (PET) evaluation following radioimmunotherapy (RIT) with ibritumomab tiuxetan Y 90 in patients with non-Hodgkin's follicular lymphoma (FL). Materials...
8.
Dewalle-Vignion A, Betrouni N, Makni N, Huglo D, Rousseau J, Vermandel M
Annu Int Conf IEEE Eng Med Biol Soc
. 2009 Jan;
2008:3122-5.
PMID: 19163368
A new automatic method for tumor volume segmentation on PET images has been developed. The method introduced in this paper is based on previous works in MRA segmentation and involves...
9.
Vermandel M, Fin L, Hapdey S, Bol A, Betrouni N, Daouk J, et al.
Med Phys
. 2008 Oct;
35(9):3922-34.
PMID: 18841843
The authors have developed a simple phantom and dedicated software for the quality assessment of positron emission tomography (PET) scanners. The phantom is a parallelepiped box filled with a relatively...
10.
Raynaud F, Huglo D, Steinling M
Rev Med Interne
. 2006 Jul;
27(12):932-45.
PMID: 16870308
Purpose: Fluorodeoxyglucose positron emission tomography (FDG-PET) is a promising imaging technique that has already proven effective in modifying patient care in oncology. Fluorodeoxyglucose still remains the main radiopharmaceutical agent routinely...